Joanne E. Tomassini

Medicine · Health Sciences

45h-index10.7kcitations178works22.62yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(91), Diabetes, Cardiovascular Risks, and Lipoproteins(46), Cancer, Lipids, and Metabolism(34), SARS-CoV-2 and COVID-19 Research(30), Pharmaceutical Economics and Policy(21)

Publications177 total

Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial
The Lancet Infectious Diseases·2024· 20 cited
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial
Open Forum Infectious Diseases·2024· 6 citedOpen Access
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
Nature Communications·2024· 32 citedOpen Access
Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults
The Journal of Infectious Diseases·2024· 35 citedOpen Access
Long-term safety and efficacy of COVE study open-label and booster phases
2024Open Access
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines
The Journal of Infectious Diseases·2024· 61 citedOpen Access
1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves
Open Forum Infectious Diseases·2023· 3 citedOpen Access
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Nature Medicine·2023· 68 citedOpen Access
Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines
2023· 79 citedOpen Access
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Nature Communications·2023· 27 citedOpen Access
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
The Lancet Infectious Diseases·2023· 52 citedOpen Access
Supplement from PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
2023Open Access
Supplement from PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
2023Open Access
Data from PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
2023Open Access
Data from PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
2023Open Access
A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273
2023· 10 citedOpen Access
Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19
2022· 12 citedOpen Access
LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
Open Forum Infectious Diseases·2022Open Access
Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
New England Journal of Medicine·2022· 23 citedOpen Access
Three-month Antibody Persistence of a Bivalent Omicron-containing Booster Vaccine Against COVID-19
2022· 21 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Jacqueline M. Miller(10), Bethany Girard(9), Rituparna Das(9), Haiyu Zhou(8), Andrew M. Tershakovec(8), Lindsey R. Baden(7), Brandon Essink(7), Weiping Deng(7), Spyros Chalkias(6), David C. Montefiori(6), Jing Feng(6), Osvaldo Flores(6), Steven S. Carroll(6), Krista Getty(6), Anne B. Eldrup(6), Balkrishen Bhat(6), Malcolm MacCoss(6), David B. Olsen(6), Rolando Pajón(5), Adam Brosz(5)